TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37910157
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (self-help booklet for quitting smoking not tailored for depression)
Study: 37910166
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (100 mg/kg body weight daily) with exercise (high-volume, moderate-intensity, whole-body exercise training 3 times per week for 8 weeks)
Study: 37910313
Drug: Tenapanor (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor (5 to 30 mg/dose, orally, twice-daily for 16 weeks)
Study: 37910822
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + Chemotherapy
Study: 37910822
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Chemotherapy
Study: 37913505
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thalidomide
Study: 37913505
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thalidomide
Study: 37913818
Drug: Arnica +
Normalized name: T-Relief Arnica +12 Plant-Based Relief Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica + Standard Therapy (ST)
Study: 37913818
Drug: Mucopolysaccharide Polysulfate
Normalized name: Mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopolysaccharide Polysulfate (MPSP) + Standard Therapy (ST)
Study: 37913936
Drug: Neuromodulators as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulators as solo therapy
Study: 37913936
Drug: Prokinetics as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetics as solo new therapy
Study: 37913936
Drug: Neuromodulators as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulators as solo new therapy with nondelayed gastric emptying
Study: 37914482
Drug: Decitabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (20 mg/m²)
Study: 37914482
Drug: 3+7 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+7 chemotherapy
Study: 37914594
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily for 5 years
Study: 37914976
Drug: NYM016 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NYM016 (novel small-molecule PSMA-targeted fluorescence probe)
Study: 37915337
Drug: eVCS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: eVCS and retinol-bakuchiol serum (RBS) combination
Study: 37915337
Drug: eVCS-RSB combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: eVCS-RSB combination
Study: 37915438
Drug: Mindfulness-based music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based music therapy (MBMT)
Study: 37915546
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 100 mg bid + Selenium 100 mcg
Study: 37915546
Drug: Resveratrol 350
Normalized name: Grape Seed Extract/Grape Skin Extract/Quercetin/Resveratrol 350 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 350 mg bid + TA-65 (Astragalus Membranaceus extract) 100U
Study: 37915619
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid
Study: 38411017
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement containing calcium, iodine, iron, β-carotene, and folic acid
Study: 37916028
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) once-weekly semaglutide
Study: 37916303
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg administered twice daily for 8 weeks
Study: 37916517
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with SBP target <120 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Study: 37916517
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with SBP target <140 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Study: 37916620
Drug: Sibeprenlimab 2
Normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibeprenlimab 2 mg/kg
Study: 37916620
Drug: Sibeprenlimab 4
Normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibeprenlimab 4 mg/kg
Study: 37916620
Drug: Sibeprenlimab 8
Normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibeprenlimab 8 mg/kg
Study: 37917058
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal.
Study: 37917058
Drug: Dostarlimab treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab treatment.
Study: 37917140
Drug: Twice-weekly outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly outpatient rehabilitation intervention (weekly physical and occupational therapy for 11 weeks)
Study: 37917140
Drug: Twice-weekly outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly outpatient rehabilitation intervention
Study: 37917187
Drug: Ivosidenib 500
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib 500 mg daily in 28-day cycles
Study: 37917218
Drug: Bone targeted
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone targeted agents (BTAs)
Study: 37917826
Drug: levcromakalim (50 µg/mL)
Normalized name: immunoglobulin G, human 50 MG/ML [Octagam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: levcromakalim (50 µg/mL)
Study: 37918404
Drug: DFMO (125-1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO (125-1,000 mg/m)
Study: 37918674
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B supplementation (2 μg daily)
Study: 37918790
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sevoflurane dose determined by anaesthesiologist)
Study: 37919269
Drug: Chemo-immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy with oleclumab (arm A)
Study: 37919269
Drug: Chemo-immunotherapy without
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy without oleclumab (arm B)
Study: 37919438
Drug: corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid injection (CSI) (n=40)
Study: 37919448
Drug: TPF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF chemotherapy followed by surgery
Study: 37919456
Drug: TTV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTV DNA load < 4.05 log10 copies/ml at ICANS onset
Study: 37919456
Drug: Falling or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falling or stable TTV DNA load between lymphodepletion and CAR-T infusion
Study: 37919483
Drug: ASC42 5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC42 5-200 mg (SAD)
Study: 37919483
Drug: ASC42 5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC42 5-50 mg (MAD) once-daily for 14 days
Study: 37919483
Drug: ASC42 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC42 15 mg with a high-fat meal
Study: 37919483
Drug: ASC42 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC42 (various doses)
Study: 37919630
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin therapy (HNC)
Study: 37919668
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg or 840 mg once daily with standard doses of everolimus for RCC
Study: 37919668
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg or 840 mg once daily with standard doses of docetaxel for GC
Study: 37919668
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg or 840 mg once daily with standard doses of cetuximab for CRC
Study: 37919668
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg or 840 mg once daily
Study: 37919695
Drug: Red blood
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red blood cell infusion
Study: 37919697
Drug: Monthly Nuvaring®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly Nuvaring® (vaginal ring)
Study: 37919697
Drug: Daily combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily combined oral contraceptive (daily pills)
Study: 37919697
Drug: Bi-monthly injectable
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-monthly injectable contraceptive (injectable)
Study: 37919697
Drug: Daily pills
Normalized name: Daily Hist Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pills
Study: 37919940
Drug: Ranibizumab intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab intravitreal therapy
Study: 37920150
Drug: Covid-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covid-19 convalescent plasma (4 units, 200-220 mL/unit, 2 units/day over two consecutive days)
Study: 37920192
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (upload glucose data weekly for 4 months, receive support from diabetes care team)
Study: 37920410
Drug: 0.15% Azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% Azelastine hydrochloride (AZE), two sprays per nostril twice daily for 4 weeks
Study: 37920410
Drug: 0.10% Azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10% Azelastine hydrochloride (AZE), dosage not specified
Study: 37920522
Drug: Algorithm Guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm Guided Treatment (AGT)
Study: 37920733
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for the transdiagnostic treatment of EDs
Study: 37920833
Drug: Betahistine 48
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 48 mg with selegiline (5 mg/d for 7 days)
Study: 37920833
Drug: Betahistine 48
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 48 mg alone
Study: 37920858
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment on days 1 and 2 in addition to standard postoperative pain management
Study: 37920963
Drug: Cannabidiol 150-300
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 150-300 mg/day
Study: 37920963
Drug: Cannabidiol 300
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 300 mg/day
Study: 37921006
Drug: ADT ON
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT ON (continuation of antiarrhythmic drug therapy)
Study: 37921006
Drug: ADT OFF
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT OFF (discontinuation of antiarrhythmic drug therapy)
Study: 37921410
Drug: PVRV-NG2 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV-NG2 (three different doses)
Study: 37921522
Drug: Perfluorohexyloctane (PFHO)
DrugBank: Perfluorohexyloctane (DB17823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluorohexyloctane (PFHO) ophthalmic drop, 1 drop 4 times daily for 52 weeks
Study: 37921599
Drug: Laparoscopic Visceral-Peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic Visceral-Peritoneal Debulking (L-VPD)
Study: 37921755
Drug: Giredestrant (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant (10, 30, 90, or 250 mg)
Study: 37921755
Drug: Giredestrant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant (100 mg) + Palbociclib (125 mg) ± LHRH agonist
Study: 37921755
Drug: Giredestrant (single-agent)
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant (single-agent) ± LHRH agonist
Study: 37921755
Drug: Giredestrant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant (100 mg)
Study: 37921846
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (VCT-based problem-solving individual therapy)
Study: 37922035
Drug: Antioxidant drug
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant drug apocynin
Study: 37922279
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention combined with progressive muscle relaxation (self-practice daily for three weeks)
Study: 37922438
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PSMA-targeting alpha emitter via antibody delivery
Study: 37922442
Drug: Adjuvant Hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Hyperthermic Intraperitoneal Chemotherapy
Study: 37922692
Drug: Targeted therapy/cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy/cancer immunotherapy
Study: 37922910
Drug: Anti-PD-1 immunotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 immunotherapy combined with standard-of-care chemo-hormonal therapy
Study: 37922910
Drug: Standard-of-care chemo-hormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemo-hormonal therapy
Study: 37922930
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of lutetium-177
Study: 37923161
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg/day, N = 45)
Study: 37923345
Drug: Fortified balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified balanced energy-protein (BEP) supplement during pregnancy and lactation
Study: 37923987
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SCRT) followed by four cycles of FOLFOX (oxaliplatin, 5-fluorouracil, and folinic acid) as a neoadjuvant treatment.
Study: 37923987
Drug: SCRT followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCRT followed by FOLFOX chemotherapy.
Study: 37924084
Drug: Inhalation LPS
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation LPS challenge
Study: 37924247
Drug: Online exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online exposure and response prevention therapy for 10 weeks
Study: 37924833
Drug: Subcutaneous TV-46000
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous TV-46000 once monthly
Study: 37924833
Drug: Subcutaneous TV-46000
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous TV-46000 once every 2 months
Study: 37924833
Drug: Subcutaneous TV-46000
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous TV-46000 (both groups)
Study: 37924841
Drug: Antibiotic exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic exposure within the past 30 days (high-risk antibiotics p=0.011 and low-risk antibiotics p=0.0004)
Study: 37924841
Drug: Antibiotic exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic exposure (adjusted odds ratio 2.75 [95% CI 1.22-6.16]) and male sex (2.75 [1.24-6.08])
Study: 37924856
Drug: MNS 10
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNS 10 mg
Study: 37925316
Drug: LVRNA009 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVRNA009 (25, 50, and 100 μg)
Study: 37925363
Drug: Ledipasvir/Sofosbuvir (LDV/SOF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir (LDV/SOF) 45/200 mg once-daily orally for 12 weeks (chemotherapy treatment group)
Study: 37925471
Drug: Tenapanor 5
Normalized name: tenapanor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 5 mg twice daily (up to 30 mg twice daily)
Study: 37925471
Drug: Tenapanor 5
Normalized name: tenapanor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 5 mg twice daily
Study: 37925512
Drug: Lung ultrasound
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound (LUS) guided surfactant therapy
Study: 37925512
Drug: Standard surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surfactant therapy
Study: 37927075
Drug: PCV13 Control
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 Control followed by a single supplemental dose of cPCV7 at 13 months
Study: 37927936
Drug: Nab-paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel plus gemcitabine (GnP-NAT), 125 mg/m²
Study: 37928549
Drug: Tixagevimab/Cilgavimab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tixagevimab/Cilgavimab 300 mg IV
Study: 37928549
Drug: Tixagevimab/Cilgavimab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tixagevimab/Cilgavimab 300 mg IM
Study: 37928549
Drug: Tixagevimab/Cilgavimab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tixagevimab/Cilgavimab 600 mg IV
Study: 37928549
Drug: Regdanvimab 40
Normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Regdanvimab 40 mg/kg IV
Study: 37928891
Drug: Oral bemnifosbuvir
Normalized name: Bemnifosbuvir
DrugBank: Bemnifosbuvir (DB19050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bemnifosbuvir (AT-527)
Study: 37928895
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (PC)
Study: 37928925
Drug: Relapse prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse prevention (RP) therapy based on cognitive behavioral treatment (CBT), comprising five to seven 45-min sessions over a period of 5 to 7 weeks.
Study: 37929672
Drug: Mirtazapine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (target 45 mg)
Study: 37929672
Drug: Carbamazepine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (target 300 mg)
Study: 37929770
Drug: Long-term home
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term home exercise program, details on dosage and duration not specified.
Study: 37929952
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg plus NUC
Study: 37930156
Drug: Nemtabrutinib 65
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemtabrutinib 65 mg daily
Study: 37930156
Drug: Nemtabrutinib (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemtabrutinib (varied doses 5 to 75 mg once daily)
Study: 37930244
Drug: High-dose protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose protein (≥ 2.2 g/kg/d)
Study: 37930244
Drug: Usual-dose protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-dose protein (≤ 1.2 g/kg/d)
Study: 37930669
Drug: Brexpiprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (2 mg/d or 3 mg/d)
Study: 37930781
Drug: Lumen voice-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumen voice-based coach delivering 8 problem-solving treatment sessions
Study: 37930792
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily documented total activity time
Study: 37931185
Drug: Circulating tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating tumor cell count-driven therapy
Study: 37931304
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy - Taking it Further (MBCT-TiF)
Study: 39252547
Drug: eIMPACT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eIMPACT intervention (internet cognitive-behavioral therapy [CBT], telephonic CBT, and select antidepressant medications)
Study: 37931632
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with pembrolizumab (n=222)
Study: 37931632
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (n=218)
Study: 37931634
Drug: Sparsentan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparsentan (400 mg oral once daily)
Study: 37931634
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg oral once daily)
Study: 37932009
Drug: Remibrutinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib (100 mg, one or two times a day)
Study: 37932258
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1467335 1 mg
Study: 37932258
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1467335 3 mg
Study: 37932258
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1467335 6 mg
Study: 37932258
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1467335 10 mg